RGEN
REPLIGEN CORP
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$179.95
+0.94%Year over year
Reported trailing growth
- Revenue
- +13.8%
- EBITDA
- -5.9%
- EBIT
- +2271.7%
- EPS
- —
- Free cash flow
- -0.2%
- Operating cash flow
- -0.8%
Forward estimates
Based on analyst estimates
- Revenue
- +27.4%
- EBITDA
- +96.7%
- EPS
- +1258.6%
Three-year CAGR
- Revenue
- -2.7%
- EBITDA
- -13.0%
- EBIT
- -35.8%
- Net income
- -35.9%
- EPS
- -36.2%
- Free cash flow
- +34.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026